LONDON, March 25 AstraZeneca has settled
a legal fight over its top-selling cholesterol drug Crestor with
generics companies, protecting revenues in the all-important
U.S. market until 2016.
Under the agreement, Watson and Egis concede that
the Crestor substance patent is valid. The settlement allows
Watson to begin selling a generic version of Crestor on May 2,
2016, at a fee to AstraZeneca of 39 percent of net sales, until
the end of paediatric exclusivity on July 8, 2016.
AstraZeneca said on Monday its partner Shionogi was
also a party to the settlement agreement.